- Report
- March 2024
- 184 Pages
Global
From €3243EUR$3,374USD£2,781GBP
€3603EUR$3,749USD£3,090GBP
- Report
- March 2024
- 250 Pages
Global
From €2586EUR$2,690USD£2,217GBP
- Report
- March 2024
- 145 Pages
Global
From €3748EUR$3,899USD£3,214GBP
- Report
- November 2023
- 139 Pages
Global
From €3061EUR$3,185USD£2,625GBP
€4373EUR$4,550USD£3,750GBP
- Report
- January 2024
- 395 Pages
Global
From €7209EUR$7,500USD£6,182GBP
- Report
- November 2023
- 173 Pages
Global
From €4710EUR$4,900USD£4,039GBP
- Clinical Trials
- April 2024
- 240 Pages
Global
From €2883EUR$3,000USD£2,473GBP
- Report
- August 2022
- 117 Pages
Global
From €4325EUR$4,500USD£3,709GBP
- Drug Pipelines
- July 2019
- 345 Pages
Global
€21145EUR$22,000USD£18,133GBP
- Report
- April 2023
- 290 Pages
Global
From €5507EUR$5,730USD£4,723GBP
- Report
- September 2019
Global
From €5161EUR$5,370USD£4,426GBP
- Report
- January 2022
- 137 Pages
Global
From €4325EUR$4,500USD£3,709GBP
- Book
- July 2009
- 1116 Pages
Lacosamide is a medication used to treat epilepsy and other seizure disorders. It is classified as an antiepileptic drug (AED) and is used to treat partial-onset seizures in adults and adolescents over 12 years of age. Lacosamide is also used to treat generalized tonic-clonic seizures in adults and adolescents over 16 years of age. It works by increasing the amount of a neurotransmitter called GABA in the brain, which helps to reduce the number of seizures.
Lacosamide is part of a larger class of drugs known as Central Nervous System (CNS) drugs. These drugs are used to treat a variety of neurological conditions, including epilepsy, Parkinson's disease, Alzheimer's disease, and multiple sclerosis. CNS drugs are typically prescribed by neurologists and other healthcare professionals.
The lacosamide market is highly competitive, with several major pharmaceutical companies offering products. Some of the companies in the market include GlaxoSmithKline, Pfizer, Novartis, Sanofi, and Johnson & Johnson. Show Less Read more
